S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
Closing prices for crude oil, gold and other commodities
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money

Cartesian Therapeutics (RNAC) Earnings Date, Estimates & Call Transcripts

$19.39
+1.35 (+7.48%)
(As of 04/12/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 2Estimated
Actual EPS
(Mar. 7)
-$2.40 Missed By -$2.10
Consensus EPS
(Mar. 7)
-$0.30
Skip Charts & View Estimated and Actual Earnings Data

RNAC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RNAC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Cartesian Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.01)($0.01)($0.01)
Q2 20241($0.01)($0.01)($0.01)
Q3 20241($0.01)($0.01)($0.01)
Q4 20241($0.01)($0.01)($0.01)
FY 20244($0.04)($0.04)($0.04)

RNAC Earnings Date and Information

Cartesian Therapeutics last released its earnings results on March 7th, 2024. The reported ($2.40) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $2.10. The firm earned $8.27 million during the quarter. Cartesian Therapeutics has generated $0.00 earnings per share over the last year. Earnings for Cartesian Therapeutics are expected to decrease in the coming year, from ($1.50) to ($2.10) per share. Cartesian Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

Cartesian Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)
------- 
3/7/2024Q4 2023($0.30)($2.40)($2.10)$1.23-$8.27 million
11/13/2023Q3 2023($1.05)($1.20)($0.15)($0.10)$9.70 million$6.55 million
8/17/2023Q2 2023($1.35)($1.05)+$0.30($0.07)$9.90 million$5.25 million
5/4/2023Q1 2023($1.20)($1.65)($0.45)($0.08)$14.60 million$5.94 million
3/2/2023Q4 2022($0.60)($0.45)+$0.15($0.10)$12.72 million$16.80 million
11/3/2022Q3 2022$0.15($0.15)($0.30)$0.03$33.00 million$20.71 million
8/4/2022Q2 2022($0.45)$0.90+$1.35$0.06$21.45 million$39.27 million
5/5/2022Q1 2022($1.35)($1.05)+$0.30($0.22)$18.82 million$34.00 million
3/10/2022Q4 2021($1.05)($0.60)+$0.45($0.11)$20.00 million$29.94 million
11/9/2021Q3 2021($1.05)($2.40)($1.35)($0.16)$13.38 million$24.43 million
8/12/2021Q2 2021($1.35)($0.60)+$0.75($0.08)$10.83 million$19.66 million
5/13/2021Q1 2021($1.80)($3.30)($1.50)($0.22)$6.88 million$11.05 million

Cartesian Therapeutics Earnings - Frequently Asked Questions

When is Cartesian Therapeutics's earnings date?

Cartesian Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on RNAC's earnings history.

Did Cartesian Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Cartesian Therapeutics (NASDAQ:RNAC) missed the analysts' consensus estimate of ($0.30) by $2.10 with a reported earnings per share (EPS) of ($2.40). Learn more on analysts' earnings estimate vs. RNAC's actual earnings.

How much revenue does Cartesian Therapeutics generate each year?

Cartesian Therapeutics (NASDAQ:RNAC) has a recorded annual revenue of $26 million.

How much profit does Cartesian Therapeutics generate each year?

Cartesian Therapeutics (NASDAQ:RNAC) has a recorded net income of -$219.71 million. RNAC has generated $0.00 earnings per share over the last four quarters.

What is Cartesian Therapeutics's EPS forecast for next year?

Cartesian Therapeutics's earnings are expected to decrease from ($1.50) per share to ($2.10) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:RNAC) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners